Phase II randomized, open-label study of cetuximab (Cet) and bevacizumab (Bev) in combination with paclitaxel (P) and carboplatin (C) in patients with stageIII/IV non-small cell lung cancer (NSCLC)

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2009
This article has no abstract
Epistemonikos ID: b9c488b9461073cf34656f3f7bc7014f11efe713
First added on: Mar 01, 2025